SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001404644-24-000049
Filing Date
2024-05-07
Accepted
2024-05-07 06:20:01
Documents
15
Period of Report
2024-05-07
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngne-20240507.htm   iXBRL 8-K 27259
2 EX-99.1 ngne_asgctpresentationxfin.htm EX-99.1 26692
6 image_0a.jpg GRAPHIC 3474
  Complete submission text file 0001404644-24-000049.txt   192892

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20240507.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20240507_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20240507_pre.xml EX-101.PRE 13050
18 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20240507_htm.xml XML 2802
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 980542593 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 24919476
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)